This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Epizyme First Look at Blood Cancer Drug Encourages

Stocks in this article: EPZM

Epizyme (EPZM) reported the first clinical data on its blood cancer pipeline candidate EPZ-6438 at the ASH Lymphoma Biology Conference last week. The drug is designed to block a specific enzyme, EZH2, which when mutated, is involved in development of certain cancers, including forms of non-Hodgkins lymphoma (NHL). Epizyme's technology platform focuses on developing drugs to regulate a class of cancer-causing enzymes known as histone methyltransferases (HMTs), of which EZH2 is just one.  

The first look at EPZ-6438 came from an early-stage (phase I) study, but was encouraging. Two of the four NHL patients reported a partial tumor response, a third patient had stable disease. The responses came from relatively low doses of EPZ-6438 and the safety profile was clean enough to allow Epizyme to continue the study using higher doses of the drug. Ideally, higher doses of EPZ-6438 should lead to more enzyme inhibition and stronger and higher frequency tumor responses. Epizyme should have results from the higher-dose cohorts of the EPZ-6438 ready to report later in the year. 

The one potential hiccup in the EPZ-6438 data presented last week was that the partial tumor responses reported came in NHL patients with "wild type" EZH2 enzyme. The stable disease patient had mutated EZH2. Ideally, the responses would have been reversed because it's mutated EZH2 thought to largely drive tumor growth. Epizyme says EPZ-6438 is capable of blocking wild-type and mutant EZH2, and there is some research suggesting both forms of the enzyme play a role in cancer growth. If this is true, seeing responses in NHL patients with wild-type EZH2 isn't surprising or concerning. However, as Epizyme enrolls more patients in EPZ-6438 studies, it will be important to see more robust responses correlating with mutated EZH2 status. This is something for investors to think about and watch going forward. 

On the other hand, if EPZ-6438 is found to be effective in patients with wild-type EZH2 tumors as well -- perhaps as part of a combination regimen with existing NHL drugs -- the commercial market opportunity might expand significantly. 

Outside of EPZ-6438, Epizyme is developing a drug with Celgene (CELG) and has three other drug candidates still in preclinical testing which are part of a partnership with GlaxoSmithKline (GSK)

Sobek is long Epizmye and Celgene.

David Sobek has been writing on biotech for a number of years through various outlets with a general focus on small cap oncology and antibiotics companies. He received his PhD in political science from Pennsylvania State University in 2003 and a BA in international relations from The College of William and Mary in 1997.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,380.41 +263.17 1.63%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs